IN RESPONSE to recent stock issues involving Mylan's Epipen autoinjector, Sun Pharma has submitted to the Mar PBAC meeting that its AdrenaJect adrenaline (epinephrine) autoinjector be listed as substitutable, "a" flagged, with the Epipen product.
SunPharma is calling on healthcare practitioners and patients to express their concerns about the single supplier situation to the PBAC at health.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 30 Jan 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Jan 18
